Trillium therapeutics logo
WebMay 5, 2024 · Investor Relations: James Parsons Chief Financial Officer Trillium Therapeutics Inc. 416-595-0627 [email protected] … WebAug 12, 2024 · TTI-621 study has progressed to the 2.0 mg/kg dosing levelTTI-622 showing early evidence of monotherapy activity$130.8 million of cash and investm...
Trillium therapeutics logo
Did you know?
WebTrillium Therapeutics Inc. (NASDAQ/TSX:TRIL) is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. We have a strong focus on CD47, a molecule that tumors frequently use to evade the immune system. CD47 is a protective “do not eat” signal that blocks the ability of certain immune cells to ... WebContact Email [email protected]. Phone Number 416-595-0627. Trillium Therapeutics Inc. operates as a biopharmaceutical research and development company. It focuses on the immune system and its regulation. The company specializes in the discovery and development of protein therapeutics, such as monoclonal antibodies, secreted ...
WebJan 18, 2024 · Overview of TTI-621 and TTI-622 Side Effects vs Competitors. Though Trillium’s therapeutics have minimal binding to red blood cells, they still retain the ability to bind to platelets and other ... WebAug 24, 2024 · Pfizer has signed a definitive agreement to acquire all the outstanding shares of clinical-stage immuno-oncology company Trillium Therapeutics for a proposed equity value of $2.26bn, or $18.50 per share, in cash.. Trillium focuses on developing advanced treatments for cancer and its portfolio comprises biologics that can boost the ability of …
WebJun 13, 2024 · 8 Trillium Therapeutics reviews. A free inside look at company reviews and salaries posted anonymously by employees. WebApr 28, 2024 · Trillium Therapeutics Inc (NASDAQ: TRIL) has provided a data update for TTI-622 and 621 programs in hematologic malignancies. As of cut-off data April 12, TTI-622 monotherapy shows a 33% objective ...
WebMay 6, 2024 · About Trillium Therapeutics. Trillium is an immuno-oncology company developing innovative therapies for the treatment of cancer. The company’s two clinical …
WebNov 17, 2024 · Acquisition enhances Pfizer’s Oncology portfolio with addition of next-generation, investigational immuno-therapeutics for hematological malignancies Pfizer … brick township construction officeWebAug 23, 2024 · About Trillium Therapeutics Trillium is an immuno-oncology company developing innovative therapies for the treatment of cancer. The company’s two clinical programs, TTI-622 and TTI-621, target CD47, a “don’t eat me” signal that cancer cells … brick township council membersWebAug 23, 2024 · Proposed acquisition strengthens Pfizer’s category leadership in Oncology with addition of next-generation, investigational immuno-therapeutics for hematological … brick township council meetingsWebTrillium Therapeutics Logo icon format. Download PNG (68.55 KB) Page last updated on: January 8th, 2024. Categories: 🇨🇦 Canada 💊 Pharmaceuticals 🧬 Biotech. brick township ecode360WebApr 8, 2024 · Cash position: Trillium completed an underwritten public stock offering on January 28, 2024, raising approximately $117 million in gross proceeds.As of March 31, … brick township code bookWebTrillium Therapeutics Inc. (NASDAQ/TSX:TRIL) is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. We have a strong … brick township demographicsWebJan 29, 2024 · Shares of Trillium Therapeutics () skyrocketed last year. After selling for $1.17 on the first trade in January, the shares clocked out at $14.71 on the last trade in December. This amazing run ... brick township dpw